Anti-tumour immunity by cytotoxic T-lymphocytes (CTLs) is essential to suppress tumour progression. Cancer cells that evade CTL immunity proliferate in the host, promoting metastasis, but mechanisms underlying this capacity remain unknown. Here we report that bladder cancer cells metastasized to lymph nodes evade CTL immunity by a new mechanism via altered glycosylation. CTLs normally recognize and kill cancer cells presenting antigenic peptides on human leukocyte antigen (HLA) class I. We show bladder cancer cells expressing the O-glycan processing enzyme, core2 b-1,6-N-acetylglucosaminyltransferase (C2GnT) exhibit HLA class I O-glycan modified with poly-N-acetyllactosamine and are highly susceptible to CTL. In those cells, poly-N-acetyllactosamine on HLA class I O-glycan binds galectin-3 to form a cell-surface molecular lattice, enabling efficient cell-surface retention of HLA class I. In contrast, bladder cancer cells in which C2GnT is downregulated show decreased levels of poly-N-acetyllactosamine on HLA class I O-glycans, attenuating lattice formation and reducing the cell-surface half-life of HLA class I. These tumour cells present antigenic peptides less efficiently, thereby evading CTL lysis and facilitating metastasis.
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Anti-tumour immunity is mediated by two distinct categories of effector cells, natural killer (NK) cell and cytotoxic T-lymphocyte (CTL). NK cells are circulating lymphocytes that protect against tumour initiation and cancer cell dissemination by detecting and eliminating transformed cells in blood stream. CD8 + CTLs specifically recognize and kill cancer cells presenting cancer cell-specific antigenic peptides, suppressing tumour progression. However, evasion of CTL attack is associated with disease progression and poor patient prognosis. Currently, several strategies used by tumour cells to evade immunity mediated by NK cells and CTLs have been identified (1) .
We previously discovered a novel mechanism used by bladder cancer cells to evade NK immunity by upregulating the O-glycan processing Golgi enzyme, core2 b-1,6-N-acetylglucosaminyltransferase (C2GnT) (2) . C2GnT acts on O-glycans to form an N-acetylglucosamine branch connected to an N-acetylgalactosamine (core2 branch). The core2 branch forms a scaffold for subsequent generation of lactosamine disaccharide repeats, poly-N-acetyllactosamine (Fig. 1A) . C2GnT upregulation promotes modification of MHC class I-related chain A (MICA), a ligand for an NK-activating receptor with poly-N-acetyllactosamine and attenuates interaction of MICA with the NK-activating receptor, enabling both evasion of NK immunity and tumour progression (2) . Another evasion mechanism of NK immunity by using cancer cell-surface glycans has been recently reported. Hudak et al. demonstrated that increasing levels of sialylated glycans on cancer cells inhibit NK cell activation by enhancing the signalling mediated by an NK inhibitory receptor, sialic acid-binding immunoglobulin-like lectin 7 (Siglec-7) (3). However, evasion of CTL immunity due to changes of cell-surface glycans has not been reported.
Immunotherapy using CTL immunity has currently become a promising therapeutic modality for cancer (4) . To induce and enhance anti-tumour CTL activity, various types of cancer vaccines, including peptide-or protein-based vaccines have been tested in cancer patients who do not respond to standard therapies. One of the successful vaccines among them is Provenge, a vaccine for castration-resistant prostate cancer (5) . In addition, T cell-surface proteins that inhibit T cell functions such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) have been identified (6, 7) . Antibodies that block CTLA-4 and PD-1 known as immune checkpoint inhibitors have proven effective against several advanced solid tumours (8) as have antibodies targeting the PD-1 ligand, anti-PD-L1 (Programmed cell death ligand-1) antibody (9) . However, CTL immunotherapy has limitations, as cancer cells utilize numerous immune evasion strategies to survive and/or neutralize a CTL attack (10) .
In the present study, we investigated the role of C2GnT in CTL tumour immunity in the metastatic sites of bladder cancer. Bladder cancer cells expressing C2GnT are highly susceptible to CTL. In contrast, cancer cells in which C2GnT is downregulated are less susceptible to CTL. Our results revealed a novel mechanism by which the metastasized cancer cells evade CTL attack.
Materials and Methods
Cells, reagents, antibodies and plasmids YTS-1 (11) and KK-47 (12) cells were generous gifts of Drs H. Kakizaki (Yamagata University) and T. Matsuo (Tohoku University), respectively. YTS-1 is an invasive bladder cancer cell with high C2GnT expression. KK-47 is a non-invasive bladder cancer cell with undetectable C2GnT expression (2) . Cells were maintained in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS, PAA Laboratories, Australia). All the biochemical reagents were purchased from Sigma-Aldrich, unless otherwise noted. Glycopeptidase F and agarose bound Lycoperiscon esculentum (Tomato) lectin (LEL-agarose) were provided by TAKARA BIO Inc. (Tokyo, Japan) and Vector Laboratories (Burlingame, CA, USA), respectively. Anti-HLA class I antibodies, clone EMR8-5 and W6/32 were purchased from Hokudo Co., Ltd. (Sapporo, Japan) and Abcam (Cambridge, UK), respectively. Anti-HLA-A24 (17A02) and anti-GAPDH (3H12) antibodies were purchased from MBL (Woburn, MA, USA). Anti-EEA1 (C45B10), galectin-3 (B2C10), galectin-1 (Rabbit polyclonal antibody) and uroplakin III (SP73) were purchased from Cell Signalling Technology (Boston, MA, USA), BD Biosciences (San Jose, CA, USA), Thermo Fisher Scientific (Waltham, MA, USA) and Spring Bioscience (Pleasanton, Cam, USA). Anti-FLAG (M2)-agarose was purchased from SigmaAldrich. The cDNAs for Human Leukocyte Antigen (HLA)-A2 and HLA-A24 (13) were provided by the RIKEN BRC through the National Bio-Resource Project of the MEXT, Japan. The stable transfectants, YTS-1 cells expressing human non-targeting siRNA (designated YTS), YTS-1 cells expressing C2GnT siRNA (C2KD), mock transfected KK-47 cells (KK47) and KK-47 cells highly expressing C2GnT (KK47C2) were previously established (2) . To prepare bladder cancer cells expressing HLA-A24, we transfected cells with HLA cDNA together with pEGFP-C2 vector (BD Biosciences, Palo Alto, CA, USA) and pTK-Hyg Vector (Clontech Laboratories, Inc., Mountain View, CA, USA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). EGFP-positive cells expressing HLA-A24 were separated using BD FACSAria (BD Biosciences, Franklin Lakes, NJ, USA) and then cultured in RPMI-1640 medium containing 10% FBS and 50 mg/ml hygromycin B for 24 days. Greater than 70% of cultured cells were positive for HLA-A24.
Analyses of bladder cancer patients
The cohort consisted of 29 patients with muscle invasive bladder cancer with positive lymph node metastasis treated with radical cystectomy and lymph node dissection at the Department of Urology, Hirosaki University Graduate School of Medicine. Health Organization System (15) . Lymph node specimens from patients were fixed with 10% buffered formalin for 1224 h. Paraffinembedded lymph node samples were cut at 3 mm and subjected to haematoxylin and eosin (HE) staining and immunohistochemistry using the monoclonal antibodies to core2 b-1,6-N-acetylglucosaminyltransferase (C2GnT) (16) and HLA class I (EMR8-5). Antimouse immunoglobulin antibody conjugated with horseradish peroxidase (Agilent Technologies Japan, Ltd., Tokyo, Japan) was used as a secondary antibody and peroxidase activity was visualized with Liquid DAB + Substrate Chromogen System (Agilent Technologies Japan, Ltd.). Based on the histochemical staining results, specimens that showed C2GnT-positive in greater than 10% of cancer cells were judged as C2GnT-positive. Lesion size in the lymph nodes was determined by HE staining. Patient survival was compared to the results of immunohistochemistry results. The institutional ethics committee of Hirosaki University Graduate School of Medicine approved this study.
CTL induction and cytotoxicity assay
We used two different HLA-A24-restricted peptides, the MAGE-3-derived peptide, IMPKAGLLI (17) and the M-phase phosphoprotein 1 (MPHOSPH1) peptide, IYNEYIYDL (18) (PH Japan Co., Ltd., Hiroshima, Japan) as antigenic peptides to bladder cancer cells. Induction of the peptide-specific CTLs was performed based on the previously described method with a slight modification (19) . Briefly, peripheral blood mononuclear cells (PBMCs) were collected from healthy HLA-A24 + volunteers using Ficoll-Paque TM PLUS (GE healthcare, HK) and cultured in RPMI-1640 medium supplemented with 10 mg/ml of one of the above peptides, 3% human serum (TAKARA BIO Inc.) and a cytokine cocktail including 100 ng/ml IL-2, 100 ng/ml IL-4, 100 ng/ml GM-CSF, 100 ng/ml TNF-a and 100 ng/ml of INF-2a (Wako, Osaka, Japan) from day 1 to 7. On day 7, lymphocytes were collected and cultured in RPMI-1640 medium supplemented with 200 ng/ml IL-2 in anti-CD3 monoclonal antibody (5 mg/ml) (OKT3)-coated culture plates from day 7 to 14. On day 14, lymphocytes were transferred to oxygen permeable culture bags. After 7 more days in culture, lymphocytes were collected as peptide-specific CTLs. Target cancer cells (1 Â 10 4 cells) were pulsed with 1 mg/ml peptide at 37 C for 1 h and then incubated with effector cells namely the appropriate peptide-specific CTLs at various ratios at 37 C for 4 h in U-bottomed 96-well microtiter plates. Release of lactated dehydrogenase from lysed target cells was measured using the Cytotox 96 Non-radioactive Cytotoxicity Assay Kit (Promega, Madison, MI, USA). All assays were performed in triplicate. Percent cytotoxicity = (experimental lactate dehydrogenase release À effector spontaneous release À target spontaneous release)/(target maximum release À target spontaneous release) Â 100. The institutional ethics committee of Oyokyo Kidney Research Institute approved this study.
Preparation of FLAG-tagged HLA-A24 and isolation of cell-surface proteins Bladder cancer cells were transfected with the cDNA constructs encoding C-terminally FLAG-tagged HLA-A24. Total lysates were prepared by solubilization in 50 mM Tris-HCl (pH7.5) containing 1% IGEPAL CA-630, 150 mM NaCl and proteinase inhibitors. Lysates were incubated with Anti-FLAG Affinity Gel (Sigma). Elution of FLAG-tagged HLA-A24 (A24F) was performed using FLAG peptide (Sigma). To isolate cell-surface proteins, cells were biotinylated using Cell Surface Protein Isolation Kit (Thermo Fisher Scientific). Biotinylated proteins were isolated with avidin-agarose. Bound proteins were released by incubating with 1Â Laemlli's SDS-PAGE sample buffer containing 50 mM dithiothreitol (DTT) and analysed by Western blotting.
Flow cytometry, immunoprecipitation and western blotting
Bladder cancer cells (1 Â 10 6 cells) were incubated with anti-HLA monoclonal antibody (W6/32) for 20 min at 4 C followed by the incubation with Alexa Fluor 488-labelled secondary antibody (Invitrogen). Cells were analysed on FACSAria. For lectin immunoprecipitation, protein samples were treated with Glycopeptidase F (40 mU/ml) to remove N-glycans and then incubated with LEL-agarose (Vector Laboratories, Burlingame, CA, USA) in 50 mM TrisHCl (pH7.5) containing 2 mM CaCl 2 , 2 mM MnCl 2 , 2 mM MgCl 2 and 150 mM NaCl. Resin-bound proteins were eluted in 1Â Laemmli's SDS-PAGE sample buffer containing 7 mM b-mercaptoethanol. To immunoprecipitate galectin-3, cell-surface proteins were cross-linked using the homobifunctional cross-linker 3,3 0 -dithiobis[sulfosuccinimidylpropionate] (DTSSP) (Thermo Fisher Scientific). Lysates were incubated with 2 mg/ml anti-galectin-3 monoclonal antibody (B2C10, BD Pharmingen) followed by the incubation with anti-mouse IgG agarose (Sigma-Aldrich). The resinbound immune complex was treated with Glycopeptidase F (40 mU/ ml) and eluted with 1Â Laemmli's SDS-PAGE sample buffer containing 7 mM b-mercaptoethanol. Lysates or protein samples were resolved by SDS-PAGE on a 412% gradient gel (Invitrogen), and transferred onto Hybond-P membranes (GE Healthcare). Western blotting was performed using specific primary antibodies and a horseradish peroxidase-conjugated secondary antibody. Signals were visualized using the ECL PLUS detection system (GE Healthcare).
Affinity of FLAG-tagged HLA-A24 for the MAGE-3-peptide FLAG-tagged HLA-A24 (A24F) proteins, A24F/KK and A24F/ KKC2 were prepared from KK-47 and KK-47C2 cells, respectively. A24F/KK and A24F/KKC2 were incubated with b2-microglobulin (Sigma-Aldrich) at a molecular ratio of 1:1 to allow complex formation. Complexes were immobilized onto a BIACORE sensor chip. MAGE-3-derived antigenic peptide (HLA-A24-restricted) was injected onto the chip and the affinity of the complexes for the peptide were analysed on BIACORE2000 (GE Healthcare). Results are expressed as resonance units (RUs), an arbitrary unit specific for the BIACORE2000 instrument.
Tumour formation in mice
Tumour formation was undertaken according to a previously described method with a slight modification (20, 21) . The peptidepulsed cancer cells (2 Â 10 6 ) and peptide-specific CTLs (4 Â 10 7 ) were mixed in 100 ml of serum-free RPMI-1640 medium and then injected into the tail vein of 6-to 7-week old NOG (NOD/Shi-scid, IL2Rg À/À ) mice (Clea Japan, Tokyo, Japan) within 5 min of mixing. After 3 weeks, lungs were harvested and fixed with 10% buffered formalin for 1224 h. To assess lung metastasis, lungs were removed and trisected and lung sections were prepared. The sections were stained with HE ( Fig. 8AG , upper panels). The degree of metastasis was evaluated by the proportion (5) of the tumour area to the total lung area on the section (21) . Paraffin-embedded mouse lung samples were cut at 3 mm and stained with HE or analysed immunohistochemically using anti-Human Uroplakin III (human bladder cancer-specific marker) staining (22) . The committee for animal experiments of Oyokyo Kidney Research Institute approved these experiments. 
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C2GnT expression in metastatic bladder cancer cells To investigate C2GnT function in metastatic bladder cancer cells, we histochemically analysed lymph node biopsy specimens from 29 bladder cancer patients using anti-C2GnT monoclonal antibody (16) .
Patients had been treated with radical cystectomy and removal of affected lymph nodes ( Table 1) . Numbers of antibody-positive cancer cells were observed in some specimens (Fig. 1B, top panel) . Based on this staining, we judged tumour specimens as antibody-positive when >10% of the cancer cells were C2GnT-positive. Thus patients were classified into two groups, C2GnT-positive (Fig. 1B, top panel) and C2GnT-negative (Fig. 1B, bottom panel) . Proliferative expansion of metastasized cells in lymph nodes is a prognostic factor in malignancies such as breast, gastric, renal and bladder cancer (23, 24) . To evaluate bladder cancer cell proliferation in lymph nodes, lymph node lesions were pathologically specified and the proportion of the cancer lesion area to total lymph node area was calculated on sections. The proportion of the lesion in C2GnT-negative cancers was significantly larger than that seen in C2GnT-positive cancers (Fig. 1C , top and middle panels), suggesting decreased proliferation of C2GnT-positive tumour cells. In addition, patients with C2GnT-negative cells in lymph node showed decreased survival relative to those with C2GnT-positive cells (Fig. 1C , bottom panel). It was previously observed that both the initial presentation of a cancer-specific antigen and cancer cell-killing by CTLs occur primarily in tumour-draining lymph nodes (25) . Taken together with this observation, our clinical data suggest that C2GnT-positive bladder cancer cells are susceptible to CTL in lymph nodes but that cancer cells showing C2GnT downregulation are less susceptible to CTL.
Evasion from CTL immunity by bladder cancer cells
To determine if cancer cells showing C2GnT downregulation evade CTL immunity, we performed a CTL cytotoxicity assay. To do so, we prepared effector CTLs specific to HLA-A24-restricted antigenic peptides, since HLA-A24 is one of the most frequent HLA class I genes and numbers of HLA-A24-restricted antigenic peptides were identified. We collected peripheral blood mononuclear cells (PBMCs) from HLA-A24 + healthy donors and then induced production of effector CTLs specific to a MAGE-3 (melanoma associated antigen-3)-derived peptide. The MAGE-3 peptide induced HLA-A24 expressing bladder cancer cell-specific CTLs (17) . To establish target cells, we used a bladder cancer cell line, YTS-1 which highly express C2GnT as a parent cell. Since YTS-1 cells barely express any types of HLA class I molecules ( Fig. 2A, lane 1) , HLA-A24 expressing cells (A24YTS) and HLA-A24 expressing cells in which C2GnT had been knocked down (A24C2KD) were prepared ( Fig.  2A, lanes 38 ). A24C2KD cells were less efficiently killed by CTLs than were A24YTS cells (Fig. 2B, top  panel) . When we used a different antigenic peptide for cytotoxicity assay, MPHOSPH1 (M-phase phosphoprotein 1)-derived peptide (18) for the cytotoxicity assay, A24C2KD cells were also less efficiently killed by CTLs (Fig. 2B, bottom panel) . We performed several control experiments using HLA-A24-non-expressing YTS-1 cells as a target cell, CTLs from HLA-A24 À donor as an effector cell and no peptides. The results from those control experiments showed that CTL toxicity was less than 10%, a background level (data not shown).
To validate these results, we assayed CTL cytotoxicity using another bladder cancer cell line KK-47 (12) which does not express C2GnT (Fig. 2C, lane 5) . HLA-A24 expressing KK-47 cells (A24KK) were also efficiently killed by CTLs than were HLA-A24 expressing cells in which C2GnT had been overexpressed (A24KKC2) (Fig. 2D) . These results overall indicates that C2GnT downregulation reduces susceptibility of bladder cancer cells to CTL lysis.
Analysis of HLA class I O-glycans
To assess C2GnT function in the response to CTLs, we focused on O-glycans of HLA class I, since HLA class I is a key molecule in antigen-presentation and C2GnT acts on only O-glycans. C2GnT promotes production of poly-N-acetyllactosamine on O-glycans by producing its scaffold, core2 branch (Fig. 1A) (2, 26) . To determine if HLA-A24 carries poly-N-acetyllactosamine on O-glycans, we transfected YTS and YTSC2KD cells with a FLAG-tagged HLA-A24 (A24F) construct. We prepared A24F proteins from YTS and YTSC2KD cells (designated A24F/YTS and A24F/C2KD, respectively) (Fig. 3A, lanes 1 and  2) . After the removal of N-glycans from A24F/YTS and A24F/C2KD with Glycopeptidase F (Fig. 3A,  lanes 3 and 4) , A24F proteins were precipitated with the Lycoperiscon esculentum (tomato) lectin (LEL) which binds specifically to poly-N-acetyllactosamine (27) (Fig. 3A, lane 5) . The amount of A24F/C2KD in the LEL immunoprecipitates was substantially lower than that of A24F/YTS (Fig. 3A, lane 6) , suggesting that A24F/YTS carries poly-N-acetyllactosamine and that C2GnT downregulation decreased levels of poly-N-acetyllactosamine on HLA-A24 Oglycan in YTSC2KD cells. We verified that this structural change of HLA-A24 O-glycan requires C2GnT activity using C2GnT-non-expressing KK-47 cells (Fig. 3A, lanes 712) . A24F from KK-47 (A24F/ KK) was undetectable in the LEL immunoprecipitates (Fig. 3A, lane 11) , but A24F from KK-47C2 (A24F/ KKC2) was detected in the immunoprecipitates (Fig.  3A, lane 12) , indicating that A24F/KKC2 carried poly-N-acetyllactosamine due to C2GnT activity.
Taking advantage of the affinity of LEL for poly-Nacetyllactosamine on O-glycans, we determined the HLA-A24 O-glycosylation site. HLA-A24 polypeptide exhibits several serine/threonine stretches. We undertook mutational analysis to narrow the O-glycosylation site to amino acids 178190, a region containing four threonine residues (data not shown). Specifically, we generated A24F mutants in which each of four threonine residues in this stretch was mutated to alanine (T178A, T182A, T187A and T190A) (Fig. 3B,  lanes 15 ). The T187A mutation specifically abrogated A24F recognition by LEL (Fig. 3B, lane 9) , indicating that it is the HLA-A24 O-glycosylation site (Fig. 3C) . We showed the domain organization and glycosylation sites of HLA-A24 by a diagram (Fig. 3C) .
Two possible mechanisms could underlie reduced susceptibility to CTL by altered O-glycosylation: impaired peptide presentation by HLA class I or reduced levels of cell-surface HLA class I expression. To test the former mechanism, we compared the affinity for antigenic peptide of HLA-A24 with and without C2GnT modification on its O-glycans (A24F/KKC2 and A24F/KK) using a surface plasmon resonancebased biosensor. No significant difference in binding affinities was seen between HLA-A24 with and without poly-N-acetyllactosamine on its O-glycans (Fig. 3D) , limiting this possibility.
Cell-surface HLA class I expression To test the latter mechanism, we histochemically analysed lymph node tissues derived from patients for HLA class I expression. Tumour cells in C2GnT-positive group expressed high levels of HLA class I, but HLA class I expression was decreased in C2GnT-negative cancer cells (Fig. 4A) . Cancer cell proliferation in lymph nodes apparently increased as HLA class I expression decreased (Fig. 4B) 
Evasion of CTLs by altered glycosylation
and A24C2KD cells. Cell-surface expression of HLA-A24 in C2GnT knockdown cells (A24C2KD) was lower than that in seen C2GnT-expressing cells (A24YTS) based on flow cytometric analysis (Fig.  4C) . The amount of HLA-A24 in biotinylated cell-surface proteins from A24C2KD cells was lower than that in A24YTS cells, although there was no difference in the amount of total HLA-A24 between A24YTS and A24C2KD cells (Fig. 4D) . These results suggest that alteration of HLA-A24 surface expression is due to decreased poly-N-acetyllactosamine on HLA-A24 Oglycans rather than an overall effect on HLA-A24 synthesis.
Intracellular trafficking of HLA-A24
Our observation of reduced cell-surface HLA-A24 expression in A24C2KD cells suggests either perturbed HLA-A24 trafficking from the Golgi apparatus to the cell surface or HLA-A24 trafficking from the cell surface to endosomes. To assess the possibilities, we analysed the kinetics of trafficking activity using a specific and reversible inhibitor, Pitstop 2-200 (PS200). PS200 blocked endocytosis of HLA class I (28). We observed the accumulation of HLA-A24 at the cell surface of YTS-1 cells in the presence of PS200 (Fig. 5A, right  panel) . It was previously demonstrated that the substitution of asparagine to glutamine at residue 86 of HLA class I which abrogates its N-glycosylation had a dramatic effect on the trafficking of HLA class I to the cell surface (29) . In fact, the surface expression of the mutated HLA-A24 lacking N-glycan at Asn86 (N86Q) was barely detected on YTS-1 cells (Fig. 5B , middle panel) and a very little accumulation of the mutated HLA-A24 at the cell surface was observed in the presence of PS200 (Fig. 5B, right panel) . In contrast, we observed the cell-surface accumulation of the mutated HLA-A24 lacking the O-glycosylation site at Thr187 (T187A) on PS200-treated YTS-1 cells (Fig.  5C, right panel) . The accumulation of HLA-A24 at the cell surface of YTS C2KD cells was also detected in the presence of PS200 (Fig. 5D, right panel) . These results suggest that there was little defect in HLA-A24 lanes 3 and 4) . GPF-treated A24Fs were immunoprecipitated with Lycoperiscon esculentum lectin (LEL)-agarose (lanes 5 and 6). A24F proteins prepared from KK and KKC2 cells (designated A24F/KK and A24F/KKC2, respectively) (lanes 7 and 8) were treated with Glycopeptidase F (GPF) (lanes 9 and 10). GPF-treated A24Fs were immunoprecipitated with LEL-agarose (lanes 11 and 12). (B) O-glycosylation site of wild-type HLA-A24. Four threonine residues were mutated separately to alanine (T178A, T182A, T187A and T190A) and mutants and wild-type proteins were prepared from YTS-1 cells (lanes 15). GPF-treated A24F proteins were immunoprecipitated with LEL-agarose. Western blots of A24F (lanes 1 and 6) and A24F mutants (lanes 25 and 710) using anti-HLA class I monoclonal antibody. (C) Domain organization of HLA-A24. HLA-A24 (341 amino acids) contains three alpha-helix domains (a1, a2, a3) and a transmembrane domain (TM). Asn86, N-glycosylation site at asparagine 86. Thr187, O-glycosylation site at threonine 187. A peptide-binding cleft is formed by a1 and a2. (D) Comparison of affinity of A24F/KK and A24F/KKC2 for the MAGE-3-derived antigenic peptide using BIACORE2000. A24F/KK and A24F/KKC2 were incubated with b2-microglobulin to allow complex formation. Complexes were immobilized onto a BIACORE sensor chip. MAGE-3-derived antigenic peptide (HLA-A24-restricted) was injected onto the chip. Results are expressed as resonance units (RUs), an arbitrary unit specific for the BIACORE2000 instrument.
trafficking to the cell surface between with and without poly-N-acetyllactosamine at Thr187 (Fig. 5AD) . To examine HLA-A24 endocytosis, we treated A24YTS and A24C2KD cells with PS200 and monitored HLA-A24 endocytosis after PS200 wash-out by evaluating HLA-A24 co-localization with EEA-1, an early endosomal marker by confocal microscopy. A24C2KD cells displayed two-fold greater HLA-A24/EEA-1 co-localization relative to A24YTS cells ( Fig. 5E and F) , suggesting that A24C2KD cells exhibit more rapid HLA-A24 endocytosis than do A24YTS cells.
HLA-A24 O-glycan mediates cancer cell-surface retention by a lectin binding mechanism
To understand a mechanism underlying the phenomenon that cells showing C2GnT downregulation exhibit more rapid HLA-A24 endocytosis than C2GnT-expressing cells, we examined whether poly-N-acetyllactosamine mediates cell-surface retention of HLA-A24 by a lectin binding mechanism. Among the N-acetyllactosamine-binding lectins, galectin-3 and galectin-1 are expressed in many types of tumour cells and bind poly-N-acetyllactosamine on N-glycans of cell-surface glycoproteins, promoting their crosslinking to form a molecular lattice that regulates their cell-surface expression (30, 31) . We incubated A24YTS cells with synthetic N-acetyllactosamine (LacNAc, Galb1-4GlcNAc) which binds galectin-3 and galectin-1. Incubation of A24YTS cells with LacNAc, but not sucrose substantially reduced cellsurface levels of HLA-A24 and galectins by competitive inhibition of galectin binding to poly-N-acetyllactosamine on HLA-A24 O-glycan (Fig. 6A) . However, incubation with anti-galectin-3 antibody, but not antigalectin-1 antibody substantially reduced cell-surface levels of HLA-A24 by depleting the cell-surface galectins (Fig. 6B) . This result taken together with a previous observation that galectin-3 and galectin-1 bind distinct cell-surface glycoproteins (32) suggest that galectin-3 dominantly forms the molecular lattice to retain HLA-A24 cell-surface retention. In fact, galectin-3 binds poly-N-acetyllactosamine on N-glycans of cell-surface glycoproteins, promoting their 
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cross-linking to form a molecular lattice structure that regulates their cell-surface retention (33, 34) .
We undertook biotinylation experiments and observed galectin-3 on the cell surface (Fig. 7A, lanes  79) . Chemical cross-linking of cell-surface proteins and subsequent immunoprecipitation using an antigalectin-3 antibody revealed that HLA-A24 bound galectin-3 on the surface of A24YTS cells (Fig. 7A,  lane 22) . Interaction of HLA-A24 with galectin-3 was decreased in A24C2KD cells (Fig. 7A, lane 23) , likely due to decreased levels of poly-N-acetyllactosamine on those O-glycans (Fig. 3A, lanes 5 and 6) . Interaction of HLA-A24 with galectin-3 was undetected in YTS cells expressing mutated HLA-A24 (T187A) (Fig. 7A, lane  24) , again likely due to lack of poly-N-acetyllactosamine modification of HLA-A24 O-glycan (Fig. 3B,  lane 9) . We stained the serial sections of lymph nodes with anti-galectin-3 monoclonal antibody. We confirmed that both HLA class I and C2GnT expressing bladder cancer cells metastasized to lymph nodes were positive for galectin-3, supporting the galecitin-3-mediated lattice formation in cancer lesions. We displayed a typical immunostaining example for lymph node section (Fig. 7B) . When lattice formation was attenuated by decreased levels of poly-N-acetyllactosamine in A24C2KD cells or by lacking of poly-N-acetyllactosamine in T187A cells, susceptibility to CTL lysis was reduced (Fig. 7C) but there was no difference in growth rate between those three cell lines (Fig. 7D ).
Cancer cells showing C2GnT downregulation evade CTL immunity in vivo
To determine if bladder cancer cells expressing low level of C2GnT evade CTL immunity and undergo metastasis, we intravenously injected the bladder cancer cells into immune-deficient NOG (NOD/Shiscid, IL-2Rg À/À ) mice, which lack T, B and NK cells and evaluated the degree of lung metastasis (see Experimental Procedures) (20, 21) . When A24YTS cells pulsed with the MAGE-3 peptide were injected, all mice exhibited lung metastases (Fig. 8B ) (degree of metastasis: 69.5%; Fig. 8H ). We then prepared the CTLs specific to the MAGE-3 peptide. When peptide-pulsed A24YTS cells were injected together with MAGE-3-specific CTLs, lung metastasis dropped to 2.3%, suggesting that CTLs efficiently killed A24YTS cells (Fig. 8C and H) . When A24C2KD or T187A cells were injected together with CTLs, lung metastasis was restored to 19.5 and 25.3%, respectively (Fig. 8E, G and H) . Given that A24YTS, A24C2KD and T187A cells exhibit comparable growth rates (2) (Fig. 7D) , our results suggest that bladder cancer cells with decreased levels of poly-N-acetyllactosamine on HLA-A24 O-glycans (A24C2KD) or that lack HLA-A24 O-glycans (T187A) evade CTL immunity in vivo and become metastatic (Fig. 8) .
Discussion
Current immunotherapeutic strategies are hampered by cancer cell evasion of CTL anti-tumour immunity. Evasion can occur via three mechanisms: (i) reduced immune recognition; (ii) upregulated immune resistance; (iii) establishment of an immune suppressive tumour microenvironment (3537). Research aimed at understanding evasion mechanisms has led to the development of new therapeutic strategies, among the most successful examples being the anti-PD-L1 antibody. Tumour cells highly expressing PD-L1 establish an immune suppressive tumour microenvironment by stimulating the PD-1 expressed on T cells (35, 38) , but anti-PD-L1 antibody blocks this activity (8) . Here we show that in bladder cancer cells with downregulated C2GnT the cell-surface half-life of HLA class I is reduced due to decreased levels of poly-N-acetyllactosamine on HLA class I O-glycan, reducing susceptibility to CTL cytotoxicity to evade CTL immunity. This novel evasion mechanism is an example of category (i), namely, reduced immune recognition.
Reduced HLA class I expression is critical for evasion of CTLs in various types of cancer (39) . Molecular mechanisms underlying reduced HLA class I expression have been extensively investigated and shown to involve defects in regulation of the HLA class I gene expression and the HLA class I protein structures (4043). We report a novel mechanism governing HLA class I cell-surface expression, specifically altered post-translational modification by O-glycosylation.
NK cells and CTLs function as cancer effectors at different phases of metastasis. NK cells detect and eliminate circulating cancer cells at early stages. CD8 + CTLs specifically kill antigenic peptide-presenting cancer cells via Evasion of CTLs by altered glycosylation sensitization, suppressing tumour growth mainly at the site of metastasis. Tumour immunogenicity is altered by the immune systems depending on the phase of metastasis, an activity called 'cancer immunoediting' (44) . Previously, we discovered a mechanism for evasion of NK antitumour immunity by C2GnT upregulation in cancer cells (2), a mechanism opposite to the mechanism relevant to CTLs. Our results suggest that bladder cancer cells evade NK immunity at an early stage and CTL immunity at a late stage by upregulating and downregulating C2GnT, respectively. At early stages of bladder cancer (Stage II and III), no metastasis was found and numbers of C2GnT-positive cancer cells were observed in bladder ( Fig. 9A and B) . In contrast, at a late stage (Stage IV), no C2GnT-positive cancer cells were observed in the metastatic sites such as lymph node (Fig. 9C) and lung (Fig.  9D) . Thus, cancer cells can likely to utilize opposing strategies in terms of C2GnT regulation to evade immune attack depending on the effector cell. We consider this opposing immunogenicity via altered glycosylation to be an example of cancer immunoediting. There are some examples that same molecules are involved in opposing immunogenicity. HLA class I molecules play opposing roles in evading NK or CTL attack. HLA class I expression suppresses NK immunity, as HLA class I is a ligand for NK-inhibitory receptors (45) . In contrast, reduced HLA class I expression promotes resistance to CTL immunity as previously described (40) and as described here.
Galectins are b-galactoside binding lectins that have been implicated in numerous biological processes. Particularly, the presence of galectin-3 reportedly correlates with malignant potential of many tumours (46) and galectins form cross-linked glycoconjugates on the cell surface that modulate various cellular processes (47, 48) . We have shown that poly-N-acetyllactosamine on HLA class I O-glycan promotes HLA class I cell-surface retention by a galectin-3-mediated mechanism (Figs. 6 and 7) . It was previously reported that binding of poly-N-acetyllactosamine on N-glycan of cytokine receptors or glucose transporter to galectins is essential for their cell-surface retention (34, 49) . A mechanism common to these activities is galectinmediated lattice formation, which delays endocytosis of cell-surface molecules, increasing their cell-surface half-life. Our results revealed that poly-N-acetyllactosamine on HLA class I O-glycan functions in cell-surface retention of HLA class I. Bladder cancer cells showing C2GnT downregulation exhibit losses in this retention mechanism due to decreased levels of poly-Nacetyllactosamine on HLA class I O-glycan.
The antigenic peptide-binding cleft of HLA class I is formed by two alpha-helix protein chains, a1 and a2 (50). The O-glycosylation site, Thr187 is located outside of the peptide-binding cleft of HLA-A24 (Fig. 3C) . This site could be suitable to retain HLA-A24 at the cell surface by the galectin-3-mediated mechanism without affecting peptide-binding. On the other hand, HLA class I N-glycan reportedly plays a critical role in protein folding and peptide loading of HLA class I and inhibition of N-glycosylation (at Asn86) decreases cellsurface appearance of HLA class I (29, 51) . 
Evasion of CTLs by altered glycosylation
In conclusion, we report important findings relevant to the role of HLA class I glycosylation in a biochemical, cell biological and immunological activities. This information should lead to elucidation of the roles of cell-surface carbohydrates in cancer and contribute to better understanding of metastasis.
